The bocx stated: "then the uncertainty of what Smithline will do and the concern related to the lack of money would be removed. With money, the company can continue its plan in China, the vet RECAF, etc."
If you are saying that new financing would eliminate the uncertainity of money issues, lets look at that some.
Moro has recently be able to get money at 5 cents. Moro has stated that he needs 3.4 million per year to operate and also pay Smithline the monthly installments.
To raise 3.4 million at 5 cents would take 60 million shares plus 60 million warrants for a total of 120 shares. That is just for the operation for one year and it would not pay off the Smithline loan. Moro would still owe over a million to Smithline and need a similar amount of funding for the following year.
Your assertion that this financing would eliminate the uncertainty of Smithline is absolutely false.
<<Biocurex anticipates that the capital requirements for the twelve months
ending September 30, 2009 will be as follows:
Research and Development - Therapeutics $ 450,000
Research and Development - Invitro diagnostics
(rapid tests, blood tests, histology tests) 700,000
Research and Development - Imagery 50,000
Payment of Outstanding Liabilities 80,000
General and Administrative Expenses 450,000
Marketing and Investor Communications 300,000
Payment of Principal on Convertible Notes 1,200,000
Payment of Interest on Convertible Notes 198,660
----------
Total: $3,428,660>>
AI
